Baina Baatrovan Lavginova

Dr. Baina Baatrovan Lavginova

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
НТНаталья Трушенко
Наталья Трушенко
OSOlga Alexandrovna Suvorova
Olga Alexandrovna Suvorova
ASAnna Shmidt
Anna Shmidt
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
ILIuliia Levina
Iuliia Levina
SASergey Avdeev
Sergey Avdeev
Background: Chronic cough is a common symptom in patients with interstitial lung diseases (ILDs), which significantly affects health-related quality of life (HRQoL). The prevalence of chronic cough varies from 30% to almost 90% in different ILDs, with the highest rate in patients with idiopathic pulmonary fibrosis. However, the pathophysiology of cough in ILDs remains poorly understood, with multiple proposed mechanisms contributing to its development. This knowledge gap complicates both clinical assessment and treatment, as current therapeutic strategies target general cough mechanisms rather than ILD-specific pathways. This review synthesizes existing data to clarify distinct cough mechanisms across ILD subtypes and identify opportunities for more targeted therapeutic strategies in this challenging patient population. Moreover, cough can be a clinical marker of disease severity and a predictor of ILD progression and transplant-free survival. Effective cough-specific therapeutic options that consider potential mechanisms, comorbidities, and individual effects on HRQoL are needed for cough associated with ILD. Therefore, the aim of this review was to analyze the prevalence, the impact on HRQoL, the pathophysiology, and the management of chronic cough in ILDs. Methods: We performed a comprehensive search in PubMed, MEDLINE, Embase, and the Cochrane Library. This review included randomized clinical trials, observational studies, systematic reviews, and meta-analyses in adults with chronic cough comparing ILD types. The following were excluded: commentaries, letters, case reports and case series, conference abstracts, and studies and publications lacking cough-specific outcomes. Results: Several approaches to reduce cough frequency and severity were described: antifibrotic agents, neuromodulators, opiates, inhaled local anesthetics, oxygen, speech therapy, and anti-reflux therapy. Some therapeutic approaches, such as oral corticosteroids and thalidomide, can cause significant side effects. Novel agents, such as P2X3 receptor antagonists, which are in phase III trials (COUGH-1/2), show promising results for refractory cough and may benefit ILD-related cough. Conclusions: Thus, a comprehensive assessment of cough is required for effective cough treatment in patients with ILDs considering possible mechanisms and individual impact on QoL.

1 July 2025 in Tuberculosis and Respiratory Diseases
Verified
Journal Article
Open access
PDF file
НТНаталья Трушенко
Наталья Трушенко
BLBaina Baatrovan Lavginova
Baina Baatrovan Lavginova
SCSvetlana Yurievna Chikina
Svetlana Yurievna Chikina
NONatalia E. Obukhova
Natalia E. Obukhova
ILIuliia Levina
Iuliia Levina
SASergey Avdeev
Sergey Avdeev
Background: Incorrect inhalation technique is a primary cause of therapeutic failure in chronic obstructive pulmonary disease (COPD), leading to increased exacerbation frequency. Identifying predictors of suboptimal peak inspiratory flow (sPIF) can significantly enhance treatment efficacy in COPD patients. The objective of this study was to identify the prevalence and predictors of sPIF in hospitalized patients with acute exacerbation of COPD in a clinical setting.Methods: This study enrolled 72 patients hospitalized for acute COPD exacerbation. It analyzed demographic, clinical, and lung function parameters. Peak inspiratory flow (PIF) was measured using an In-Check DIAL G16 (Alliance Tech Medical) across different resistance levels of the patients’ inhalation devices, both before and after instruction in inhalation technique, and at various resistance settings (R2 and R5) upon admission and discharge.Results: Initially, 52.7% of patients exhibited sPIF, which decreased to 19.4% following inhalation technique education (p70 years, forced vital capacity <73% predicted (pred.), forced expiratory volume in 1 second (FEV1) 194% pred., RV/total lung capacity >70%, and diffusing capacity for carbon monoxide <36% pred. as independent predictors of sPIF. The most significant predictors were age (odds ratio [OR], 0.89) and FEV1 (OR 0.59).Conclusion: Selecting a suitable dry powder inhaler for maintenance therapy in patients with acute exacerbation of COPD requires consideration of the patient's ability to achieve optimal PIF, with special attention to age and severity of functional impairment.

21 June 2025 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
OSOlga Alexandrovna Suvorova
Olga Alexandrovna Suvorova
НТНаталья Трушенко
Наталья Трушенко
BLBaina Baatrovan Lavginova
Baina Baatrovan Lavginova
ILIuliia Levina
Iuliia Levina
ZMZamira M. Merzhoeva
Zamira M. Merzhoeva
SASergey Avdeev
Sergey Avdeev
Background. Idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) are interstitial lung diseases with similar symptoms: dyspnea and cough, which determine disease severity and serve as prognostic markers. Aim. To compare clinical and functional characteristics and their dynamics in patients with IPF and different HP phenotypes, and to assess the relationship between symptoms and objective test results. Materials and methods. A longitudinal observational study included 153 patients (48 with IPF, 105 with HP, including 72 fibrotic HP [fHP], of whom 32 had a UIP pattern). Demographic, anamnestic, and functional parameters (spirometry, body plethysmography, DLco) were analyzed. Dyspnea (mMRC scale), cough (VAS and LCQ questionnaire), 6MWT results, HRCT changes, and echocardiographic signs of right heart dysfunction were assessed at baseline and after 12 months. Statistical analysis included nonparametric tests, Spearman correlation, and multiple linear regression to evaluate the impact of parameters on dyspnea and cough. Results. Patients with fHP and fHP+UIP did not significantly differ from IPF patients in dyspnea severity (mMRC), cough intensity (VAS), or functional parameters. Mortality and disease progression were comparable between IPF, fHP, and fHP+UIP groups. Dyspnea severity correlated with GAP scores, 6MWT distance, SpO2 at baseline and end of 6MWT, presence of fibrosis on HRCT, functional parameters (DLco, CPI, etc.), and Charlson Comorbidity Index. Regression analysis showed that end-exercise SpO2 and pulmonary fibrosis had the greatest impact on dyspnea. Cough correlated with fibrosis, dyspnea (mMRC), and functional parameters (FVC, FEV1, CPI). FEV1 and pulmonary fibrosis were the most significant predictors of cough severity. Conclusion. Patients with fHP, particularly those with a UIP pattern, have comparable functional impairment and clinical manifestations to IPF patients. Dyspnea and cough are closely associated with exertional desaturation, functional parameters, and pulmonary fibrosis on HRCT, which should be considered when evaluating HP and IPF.

Verified
Journal Article
Open access
PDF file
EKElena Kondatyeva
Elena Kondatyeva
SASergey Avdeev
Sergey Avdeev
TKTatiana A. Kyian
Tatiana A. Kyian
OROxana Ryzhkova
Oxana Ryzhkova
YMYuliya Melyanovskaya
Yuliya Melyanovskaya
SKSergei I. Kutsev
Sergei I. Kutsev
Primary ciliary dyskinesia (PCD) is a rare hereditary disorder belonging to the group of ciliopathies, with autosomal recessive, autosomal dominant, and, less frequently, X-linked inheritance patterns. The aim of this study was to investigate the genetic heterogeneity of the Russian population of PCD patients based on national registry data. The study included patients with PCD confirmed by molecular genetic testing. Quantitative data were analyzed using non-parametric statistical methods. Differences were considered statistically significant at p < 0.05. The study included 109 patients with PCD. Molecular genetic testing identified pathogenic variants in 29 autosomal recessive genes. The analysis of pathogenic variant distribution in the Russian PCD cohort revealed the highest number of changes in the DNAH5 and DNAH11 genes. 26 genetic variants in 13 genes were identified for the first time in the Russian population. Variants in the DNAH5 gene were significantly more frequent in Kartagener’s syndrome (KS) patients (32/55%) compared to those without KS (11/21.5%) (χ2 = 12.8; p = 0.0004; OR = 4.48). Preliminary data indicate that the frequency spectrum of DNAH5 and DNAH11 genes in Russian patients is similar to international trends. Additionally, there is an accumulation of pathogenic variants in the DNAH5, DNAH11, CCDC39, and CFAP300 genes.

15 November 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
НТНаталья Трушенко
Наталья Трушенко
BLBaina Baatrovan Lavginova
Baina Baatrovan Lavginova
GNG. S. Nuralieva
G. S. Nuralieva
SASergey Avdeev
Sergey Avdeev
Chronic Obstructive Pulmonary Disease (COPD) is a chronic condition characterized by persistent airflow limitation, caused by chronic inflammation in response to exposure to inhaled damaging particles or gases. Exacerbations of COPD lead to the progression of symptoms, worsening lung function, reduced physical tolerance, and, as a result, contribute to an increase mortality. Therefore, the prevention of exacerbations is a primary objective in the management of COPD. The foundation of COPD therapy involves prescribing long-acting bronchodilators, and for some patients, the use of anti-inflammatory agents, such as inhaled corticosteroids (ICS). ICS are used in combination with long-acting beta2-agonists (LABA) or as part of triple therapy (ICS/LABA/ LAMA). The choice of triple therapy depends on the patient’s exacerbation history, severity of symptom, level of peripheral blood eosinophilia, risk of infectious complications, and the presence of a concomitant diagnosis of bronchial asthma. Triple therapy offers advantages in terms of improving lung function, disease symptoms, reducing exacerbation frequency, and significantly decreasing mortality compared to other inhaled therapy options for COPD. A significant advantage of this therapy has been shown in patients with eosinophilic COPD. Currently, three combined inhalation medications containing ICS/LABA/LAMA are available for COPD treatment in our country. This review provides basic information on the clinical efficacy and safety profile of one of them, budesonide/glycopyrronium bromide/formoterol, in patients with various COPD phenotypes.

10 December 2024 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
НТНаталья Трушенко
Наталья Трушенко
BLBaina Baatrovan Lavginova
Baina Baatrovan Lavginova
OBO. S. Belkina
O. S. Belkina
SASergey Avdeev
Sergey Avdeev
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition characterized by persistent airflow limitation caused by chronic airway inflammation in response to harmful particles and gases. The diversity of clinical manifestations and pathophysiological mechanisms necessitates an individualized approach to treatment. The disease is driven by inflammatory processes, including the activation of macrophages, neutrophils, and T-cells, as well as the release of various inflammatory mediators that contribute to chronic airway damage. In recent years, attention has turned to eosinophilic inflammation, traditionally associated with asthma, which is also found in a significant portion of COPD patients. Eosinophilia is observed in a considerable number of COPD patients and is associated with more severe disease and an increased risk of exacerbations. However, data on the role of eosinophils in COPD are mixed: some studies find no difference in disease severity between high- and low-eosinophil groups, while others confirm an elevated risk of exacerbations in patients with high eosinophil levels. A promising therapeutic agent in this area is dupilumab — a monoclonal antibody that blocks interleukin-4 and -13 receptors, demonstrating the ability to reduce exacerbation frequency and improve lung function in COPD patients by targeting eosinophilic inflammation. Clinical trial results indicate that dupilumab provides significant clinical improvement and may become an important tool in treating eosinophilic COPD, offering a new approach based on the molecular understanding of the disease. This publication presents the latest data on the use of dupilumab in COPD treatment.